Interpace Diagnostics Group, Inc.(US:IDXG) Globenewswire·2025-12-03 17:12Core Viewpoint - Interpace Biosciences has successfully repaid its outstanding term loan facility with BroadOak Capital Partners ahead of schedule, enhancing its financial position and operational flexibility for future growth [1][2][3]. Financial Performance - The early repayment of the loan eliminates related interest expenses, which is expected to provide increased operational flexibility for the company [2]. - The repayment is described as a significant milestone, reflecting the company's robust financial performance and disciplined capital management [3]. Strategic Partnerships - BroadOak Capital Partners has been a valuable partner in supporting Interpace's strategic turnaround and transition to profitability [3]. Business Focus - With the debt retired, the company aims to focus its resources on driving commercial growth, particularly in delivering record testing volumes and revenue for its thyroid tests [3]. Company Overview - Interpace Biosciences is positioned as an emerging leader in personalized medicine, offering specialized services from early diagnosis to targeted therapeutic applications [4]. - The company provides clinically useful molecular diagnostic tests and bioinformatics services for cancer risk evaluation, leveraging advanced technology for improved patient management [5].